Source access required
CVR360 has not loaded official Danish source data for this company yet. No AI or financial conclusion is generated without source-backed facts.
RP
ResoTher Pharma A/S
aktivCVR 37852406AktieselskabDronninggårds Alle 136, 2840 HolteForskning og eksperimentel udvikling inden for naturvidenskab og teknik
- Latest accounts
- 2024
- Statement scope
- Standalone
- Verified
- 06 Nov 2026
- Sources
- 5
What changed?
Source-backed changes, not an assessment.
1 source
Key figures
Latest period: 2024
Revenue
Not disclosed—
Not disclosed
Operating profit
DKK -12.8m
Latest period
Source details
Source: dk-regnskabsdata-live-37852406-1793935166492
Document: dk-regnskabsdata-37852406-AZgNxLbDhegZy6r8J_CL-1
XBRL: ifrs-full:ProfitLossFromOperatingActivities
Period: 01 Jan 2024 - 31 Dec 2024
Technical details
Context: ctx1
Unit: vDKK
Net result
DKK -10.1m
Latest period
Source details
Source: dk-regnskabsdata-live-37852406-1793935166492
Document: dk-regnskabsdata-37852406-AZgNxLbDhegZy6r8J_CL-1
XBRL: ifrs-full:ProfitLoss
Period: 01 Jan 2024 - 31 Dec 2024
Technical details
Context: ctx1
Unit: vDKK
Equity
DKK 12.1m
Equity ratio: 81.6%
Source details
Source: dk-regnskabsdata-live-37852406-1793935166492
Document: dk-regnskabsdata-37852406-AZgNxLbDhegZy6r8J_CL-1
XBRL: ifrs-full:Equity
Period: 01 Jan 2024 - 31 Dec 2024
Technical details
Context: ctx10
Unit: vDKK
Development
Reported values. Missing periods appear as gaps.
RevenueNet result
Tabular view of development
| Year | Revenue | Net result |
|---|---|---|
| 2023 | — | DKK -17.5m |
| 2024 | — | DKK -10.1m |